Menu10/20/16: The US Securities and Exchange Commission has emerged as a real powerhouse in the anti-corruption actions of the US government. True, the SEC’s enforcement of the books and records provision of the FCPA lacks the dark drama of the actual bribery provisions of the law, but SEC has real muscles under that accountants’ cloak – and no industry feels those muscles more directly than the pharmaceutical industry. A publication by Gary Giampetruzzi, S. Joy Dowdle & Katherine K. Solomon from global law firm Paul Hastings uses the recent AstraZeneca settlement to illustrate SEC’s thinking and actions in enforcing anti-corruption laws.
